Network meta-analysis ranks B-cell biologics for lupus efficacy and safety

A systematic review and network meta-analysis published in Egyptian Rheumatology and Rehabilitation has compared three B-cell-targeted biologic agents—belimumab, rituximab, and telitacicept—in patients with systemic lupus erythematosus (SLE) or lupus nephritis, drawing on fifteen randomized controlled trials that enrolled a total of 6,455 patients. Because no direct head-to-head trials exist among these agents, the researchers used a network meta-analysis, a statistical framework that allows indirect comparison of multiple treatments through shared comparators, in this case placebo plus standard therapy. The work, led by Bingbing Deng, Zhihang Xiao, Hongru Wang, and Qingli Lu, was reported on 8 October 2026 as an open-access review.

The primary efficacy outcome was the Systemic Lupus Erythematosus Responder Index-4 (SRI-4) response rate at approximately 52 weeks, a composite measure of disease activity improvement. Secondary outcomes included the severe flare index, the proportion of patients achieving glucocorticoid dose reduction, and improvement in fatigue measured by the FACIT-Fatigue scale. Safety was assessed through the incidence of total adverse events and serious adverse events. The team searched PubMed, Embase, Web of Science, the Cochrane Library, and the Chinese databases CNKI and Wanfang from database inception to September 2025, including only randomized controlled trials and screening 2,420 initial records down to the final fifteen trials.

The analysis employed two complementary statistical frameworks. Efficacy comparisons were conducted with a Bayesian network meta-analysis using Markov chain Monte Carlo methods, expressing treatment effects as odds ratios with 95% credible intervals, while safety outcomes were analyzed with a frequentist network meta-analysis in R using the netmeta package, a choice made because adverse event data often contain zero-event trials that can cause convergence problems in Bayesian models. Treatment rankings were estimated using the surface under the cumulative ranking curve (SUCRA) for efficacy and P-scores for safety. Convergence was verified with Gelman-Rubin diagnostics, and a design-by-treatment interaction model found no evidence of global inconsistency for the primary endpoint.

The headline finding was that telitacicept, a recombinant TACI-Fc fusion protein that simultaneously blocks the B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) pathways, achieved the highest SUCRA ranking for SRI-4 response, at 0.985. In pairwise analysis, telitacicept 160 mg subcutaneous plus standard therapy improved SRI-4 response rates versus placebo with an odds ratio of 6.28 (95% CI 3.20–12.33), based on two trials with moderate heterogeneity (I2 = 56%). However, the authors explicitly caution that this probabilistic ranking should not be interpreted as definitive evidence of superior efficacy, because the contributing evidence was limited to a small number of trials and relied largely on indirect comparisons.

That greater apparent efficacy came at a safety cost. Telitacicept showed a significantly higher incidence of total adverse events versus placebo (OR = 2.13, 95% CI 1.18–3.83), and in the safety network it ranked lowest on the P-score hierarchy. Compared with belimumab 10 mg/kg intravenous, telitacicept was the only treatment that significantly increased the risk of total adverse events, with an odds ratio of 2.36 (95% CI 1.24–4.49). No statistically significant difference in serious adverse events was observed for telitacicept versus placebo (OR = 0.61, 95% CI 0.34–1.08). The authors attribute the higher adverse event burden to the drug’s broader immunosuppressive activity and emphasize the need for careful patient selection and close safety monitoring.

Belimumab, a monoclonal antibody that neutralizes soluble BLyS and was the first biologic approved for SLE, demonstrated consistent efficacy across dosages and routes of administration. At 10 mg/kg intravenous, pooled analysis of eight trials showed a significant SRI-4 advantage over placebo (OR = 1.68, 95% CI 1.43–1.97), a reduced risk of severe flares (OR = 0.70, 95% CI 0.53–0.92), and increased glucocorticoid dose reduction (OR = 1.54, 95% CI 1.10–2.16), with no significant differences in total or serious adverse events. The 1 mg/kg intravenous dose also improved SRI-4 response (OR = 1.46, 95% CI 1.16–1.82) and glucocorticoid sparing (OR = 1.79, 95% CI 1.17–2.76).

The 200 mg subcutaneous formulation emerged as the most balanced option. Across two trials it significantly increased SRI-4 response rates (OR = 1.78, 95% CI 1.39–2.28), reduced severe flares (OR = 0.46, 95% CI 0.33–0.64), improved glucocorticoid dose reduction (OR = 1.76, 95% CI 1.12–2.77), and improved fatigue (OR = 1.47, 95% CI 1.15–1.89). Notably, serious adverse events occurred less frequently than with placebo (OR = 0.60, 95% CI 0.43–0.84), while total adverse events showed no significant difference. In the safety network, belimumab 200 mg subcutaneous had the most favorable P-score ranking. The authors suggest the lower serious adverse event rate may partly reflect improved disease control and reduced cumulative glucocorticoid exposure.

Rituximab, an anti-CD20 monoclonal antibody that depletes circulating B cells and is widely used off-label in refractory SLE, presented a different picture. Because the rituximab trials did not report SRI-4 responses, the drug could not be included in the primary efficacy network. In the available randomized evidence, rituximab showed no statistically significant differences from placebo in British Isles Lupus Assessment Group (BILAG) global scores (mean difference = 0.10, P = 0.84) or SF-36 physical component summary scores (standardized mean difference = 0.09, 95% CI −0.12 to 0.29). Its safety profile was comparable to standard therapy, with no significant differences in total or serious adverse events across two trials in SLE or lupus nephritis populations.

The authors are careful to stress that the rituximab findings indicate an absence of demonstrated benefit in the evaluated outcomes, not evidence of no treatment effect. The randomized trials enrolled specific patient populations receiving substantial background standard therapy, whereas rituximab is also used clinically in selected patients with refractory disease, including lupus nephritis and hematologic manifestations. Mechanistically, the three agents differ in ways that may explain the observed hierarchy: belimumab selectively inhibits BLyS and primarily affects mature B-cell survival, rituximab depletes CD20-positive B cells but does not directly target long-lived plasma cells, and telitacicept blocks both BLyS and APRIL, potentially providing broader suppression of autoreactive B-cell and plasma-cell activity.

Several limitations frame these conclusions. The review protocol was not prospectively registered, most treatment comparisons were indirect because head-to-head trials remain unavailable, and certainty of evidence was not formally assessed with GRADE or CINeMA frameworks. The primary SRI-4 network consisted predominantly of general SLE populations, while both SLE and lupus nephritis populations contributed to the safety network, introducing clinical heterogeneity that warrants caution when extrapolating results specifically to lupus nephritis. Long-term outcomes such as sustained remission, organ damage accrual, and long-term safety were inconsistently reported, and obinutuzumab was excluded because it fell outside the predefined intervention scope. The authors call for direct comparative trials, standardized organ-specific outcome definitions, and real-world evidence and post-marketing surveillance, particularly for newer agents such as telitacicept, and emphasize that treatment selection should account for disease phenotype, renal involvement, severity, prior response, and safety rather than overall rankings alone.

Subject of Research: Comparative efficacy and safety of B-cell-targeted biologics in systemic lupus erythematosus and lupus nephritis

Article Title: Comparative efficacy and safety of B-cell-targeted biologics in systemic lupus erythematosus: a systematic review and network meta-analysis

Article References: Deng, B., Xiao, Z., Wang, H., & Lu, Q. (2026). Comparative efficacy and safety of B-cell-targeted biologics in systemic lupus erythematosus: a systematic review and network meta-analysis. Egyptian Rheumatology and Rehabilitation, 53(1), Article 84. https://doi.org/10.1186/s43166-026-00455-4

Image Credits: AI Generated

DOI: 10.1186/s43166-026-00455-4

Keywords: systemic lupus erythematosus, lupus nephritis, belimumab, rituximab, telitacicept, network meta-analysis, SRI-4, B-cell-targeted therapy, adverse events, SUCRA ranking, randomized controlled trials, BLyS